Sure, as long as you accept some failure rate. Maybe 80% success for 25mer peptides from a good manufacturer (e.g. JPT, SciTide, &c). For DNA it probably varies by technology, not sure what % of sequences are high purity manufactured as eg mbDNA. Not as sure about RNA but haven’t an RUO failure yet

What else kinda fits this paradigm?

Bacteriophage screening?

N-of-1 ASOs?

What else?

Personalized neoantigen targeting TCR therapies (less common) go further by actually having a distinction between target and therapeutic but the TCR is not yet computationally designed (instead isolated from the patient) and manufacturing is rough (GMP cell therapy hell)

Neoantigen vaccines come closest to embodying this paradigm but kinda cheat by making the targets and therapeutics the same thing.

Also, they don’t really work yet (which makes lack of meaningful safety screening less of a problem)

Oh these are good!

Sure! I always forget pubpeer exists but it’s a good idea

But it’s getting really subtle!

Soft focus is the biggest tell of this generation unless you look closely

My mom, upon hearing her grandchildren singing “undzer liber khaver Stalin”, would be torn between amusement and disowning the lot of us — she would ultimately choose the latter

Zoom in a bit and look at eg ears

I like figuring out why all the Cell/Nature/Science retrospective studies are fake but don’t have time to then argue with a motivated obfuscator about it

Effects of the behavioral correlates are harder to study but strong hints of big non-COVID mortality risk here: www.cdc.gov/mmwr/volumes...

They remarkably don’t address either flavor of confounding wrt foregoing Covid vaccines in 2021/2022

But it definitely does matter wrt mortality from confirmed infection:

ascopubs.org/doi/10.1200/...

www.jcancer.org/v14p2410.pdf

Agree on both points!

I think the IFN response they dig into is probably a very important adjuvant effect of mRNA vaccines & in a larger cohort you probably would see some survival difference when combined with ICI in cancer patients.

But this paper had to juice the effect size with confounders

Nothing, I made a whole class of stuff like this published in Nature and Science: github.com/iskandr/bcb731

I can't imagine that an older lung cancer patient foregoing Covid vaccination in ~2021 was otherwise the same health profile as people who got vaccinated.

And even if they were somehow comparable -- then they still wouldn't have immunity to SARS-CoV-2 during peak Covid.

Nah, I can imagine the multi-year back and forth over whether they really controlled for the infinite confounders.

cf. it took Keith Baggerly years of extremely stubborn persistence to get acknowledgement of the really brazen flaws in Anil Potti's stuff, I don't have time for that